ACRS vs SCD Comparison

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Lmp Capital & Income Fund Inc is a United States-based non-diversified, closed-end management investment company. Its investment objective is total return with an emphasis on income. The fund invests in a broad range of equity and fixed-income securities of both the U.S. and foreign issuers. Its long-term investments consists of investments in common stocks, convertible preferred stocks, investments in underlying funds and master limited partnerships. Maximum investment in Sales in the IT sector, Cheniere Energy in the energy sector, Ares Management and U.S. Bancorp in the financials sector and Lennar in the consumer discretionary sector, and etc.